Yükleniyor... / Loading...
This study analyzes genetic differences between patients with Dravet syndrome who respond to a cannabis strain (Charlotte's Web) and those who do not. People aged 1-50 with gene-confirmed Dravet syndrome and uncontrolled epilepsy who were seeking Charlotte's Web therapy were able to take part. It was conducted as a study with no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * age 1-50 with gene confirmed Dravet Syndrome * uncontrolled epilepsy, having failed at least 2 prior treatments (including appropriate Anti-epileptic drugs, ketogenic diet, vagus nerve stimulation Therapy) * Seizure frequency should be more than 2 visually countable motor seizures per week (tonic clonic, tonic, clonic, myoclonic, or astatic) * care providers able to identify convulsive seizures, drop attacks, or tonic seizures, or any combination of countable seizure types * self- seeking therapy with Charlotte's Web strain of medical marijuana with the assistance of a medical marijuana doctor, but are still naïve to therapy * care provider able to complete seizure count diary * able to obtain oral swab sample from subject with Dravet Syndrome * agree to forfeit any right to results of genetic analysis Exclusion Criteria: * subjects having non-epileptic seizures that are not distinguishable from epileptic seizures by the care provider * prisoners * pregnant women * failure to forfeit right to results of genetic analysis